Clinical spectrum and treatment of thyroid lymphoma: results of a cohort study of 61 patients - Takeaways - MDSpire

Clinical spectrum and treatment of thyroid lymphoma: results of a cohort study of 61 patients

  • By

  • Shuchang Li

  • Wenjie Gu

  • Zhenzhen Yang

  • Honghan Qiao

  • Feiyang Zong

  • Shifeng Hao

  • Yuxiao Chang

  • Wanyue Zhao

  • Xiang Gao

  • Xudong Zhang

  • Qingjiang Chen

  • June 10, 2026

  • 0 min

Share

  • 1

    Thyroid lymphoma (TL) is a rare malignancy, comprising 1% to 5% of thyroid cancers and less than 2% of extranodal lymphomas.

  • 2

    67.2% of patients with TL in the study had concurrent Hashimoto’s thyroiditis, indicating a common association.

  • 3

    The study found that chemotherapy significantly improved progression-free survival (PFS) and overall survival (OS) in patients with thyroid diffuse large B-cell lymphoma.

  • 4

    Older age (≥60 years) and high C-myc expression (≥50%) were identified as independent risk factors for shorter PFS in patients with thyroid diffuse large B-cell lymphoma.

  • 5

    Management of TL with extrathyroidal involvement requires Ann Arbor staging and a multidisciplinary approach for optimal treatment outcomes.

Original Source(s)

Clinical spectrum and treatment of thyroid lymphoma: results of a cohort study of 61 patients

  • by Shuchang Li, Wenjie Gu, Zhenzhen Yang, Honghan Qiao, Feiyang Zong, Shifeng Hao, Yuxiao Chang, Wanyue Zhao, Xiang Gao, Xudong Zhang, Qingjiang Chen

  • June 10, 2026

Related Content

Current treatment landscape and translational priorities in malignant rhabdoid tumor of the kidney

AAT score based on pretreatment indicators predicts outcomes in unresectable HCC patients treated with TACE, Sintilimab, and Bevacizumab

Subcutaneous patient-controlled analgesia with hydromorphone for the treatment of refractory cancer pain in older hospitalized patients: a retrospective real-world study